AIM:To systematically evaluate the association between the miR-146 a rs2910164 polymorphism and susceptibility to gastric cancer.METHODS:A comprehensive electronic search was conducted for articles published up until ...AIM:To systematically evaluate the association between the miR-146 a rs2910164 polymorphism and susceptibility to gastric cancer.METHODS:A comprehensive electronic search was conducted for articles published up until January 27,2014 in Medline(PubMed),Excerpta Medica Database(Embase),the Cochrane Library and Google Scholar.Only case-control studies published in English that evaluated the association between the miR-146 a rs2910164 polymorphism and susceptibility to gastric cancer were included.Furthermore,only studies with sufficient data allowing for calculation of odds ratio(OR) and corresponding 95% confidence interval(CI) were included.These values were used in the quantitative synthesis to assess the strength of the association between the miR-146 a rs2910164 polymorphism and risk of gastric cancer.RESULTS:The database search identified 1002 eligible studies,of which seven(comprising 4112 cases and 5811 controls) were included for the meta-analysis.The results indicate that miR-146 a rs2910164 polymorphism is more likely to be associated with gastric cancer risk.In the overall analysis,a significantly increased cancer risk was found in the heterozygote(GG vs GC) comparison(OR = 1.14,95%CI:1.03-1.27; P = 0.01 for pooled OR).In the ethnicity subgroup analysis,a similar result was found among Caucasians(OR = 1.36,95%CI:1.01-1.85; P = 0.04 for pooled OR).In the stratified analysis by quality of studies,a significantly increased cancer risk was found in the heterozygote comparison among high quality studies(OR = 1.12,95%CI:1.01-1.26; P = 0.04 for pooled OR).When stratified on the basis of sample size,a significantly increased cancer risk was found among small sample size subgroups for the allelic(G vs C:OR = 1.16,95%CI:1.03-1.30; P = 0.01),homozygote(GG vs CC:OR = 1.33,95%CI:1.03-1.73; P = 0.03) and recessive model(GG vs GC + CC:OR = 0.05,95%CI:0.00-0.10; P = 0.03) comparisons.CONCLUSION:The miR-146 a rs2910164 polymorphism is associated with increased gastric cancer risk,particularly evident in high quality studies with small sample sized Caucasian populations.展开更多
目的系统评价香砂六君子汤联合化疗治疗中晚期胃癌的安全性和疗效性,并通过GRADE质量评价分析证据等级。方法检索中国知网、万方数据知识服务平台、维普中文科技期刊数据库(中文科技期刊数据库)、PubMed、Cochrane Library、Web of Scie...目的系统评价香砂六君子汤联合化疗治疗中晚期胃癌的安全性和疗效性,并通过GRADE质量评价分析证据等级。方法检索中国知网、万方数据知识服务平台、维普中文科技期刊数据库(中文科技期刊数据库)、PubMed、Cochrane Library、Web of Science数据库建库至2023年7月发表的文章,利用EndNote X9、Review Manager 5.3软件进行文献筛选与剔除、meta分析。结果共纳入18篇文献,研究例数共1430例,其中研究组717例,对照组713例。meta分析结果显示,香砂六君子汤联合化疗可以提高肿瘤治疗有效率(OR=2.17,95%CI:1.65~2.85,P<0.00001)、中医症候评分(OR=4.89,95%CI:2.40~9.98,P<0.0001)及生活质量(MD=6.40,95%CI:4.19~8.60,P<0.00001),减少恶性呕吐(OR=0.14,95%CI:0.08~0.24,P<0.0001)和白细胞减少的发生数(OR=0.35,95%CI:0.17~0.72,P=0.005),主要是减少Ⅲ~Ⅳ级的白细胞减少发生数(OR=0.22,95%CI:0.12~0.38,P<0.00001),但对腹泻(OR=0.31,95%CI:0.09~0.32,P<0.00001)的meta分析有统计学意义,但无显著性差异。结论香砂六君子汤联合化疗可以提高晚期胃癌治疗的效果,减少不良反应的发生,给临床治疗胃癌提供了理论依据。展开更多
目的系统评价新型口服抗凝药(达比加群酯、利伐沙班、阿哌沙班及依度沙班)用于非瓣膜性房颤治疗的有效性和安全性。方法计算机检索截止2016年9月,在Pubmed,Embase,Medline,Cochrane,Clinical Trials.gov,Web of Science,中国知网、万方...目的系统评价新型口服抗凝药(达比加群酯、利伐沙班、阿哌沙班及依度沙班)用于非瓣膜性房颤治疗的有效性和安全性。方法计算机检索截止2016年9月,在Pubmed,Embase,Medline,Cochrane,Clinical Trials.gov,Web of Science,中国知网、万方及维普数据库中检索关于新型口服抗凝药用于非瓣膜性房颤治疗的随机对照研究,根据纳入标准和排除标准对文献进行筛选和质量评价,使用Rev Man 5.3和Stata 13.1软件对数据进行网络Meta分析。结果共纳入17篇随机对照研究,总计83 561例患者。网络Meta分析结果显示,新型口服抗凝药预防全因死亡率的作用按照由高至低依次排序为利伐沙班,阿哌沙班,依度沙班,达比加群酯;治疗卒中和体循环栓塞的作用按照由高至低依次排序为利伐沙班,达比加群酯,阿哌沙班,依度沙班;治疗缺血性卒中的作用按照由高至低依次排序为利伐沙班,阿哌沙班,达比加群酯,依度沙班;严重出血率按照由低至高依次排序为依度沙班,阿哌沙班,达比加群酯,利伐沙班;颅内出血率按照由低至高依次排序为达比加群酯,依度沙班,阿哌沙班,利伐沙班;心肌梗死率按照由低至高依次排序为利伐沙班,阿哌沙班,依度沙班,达比加群酯。所有结局指标的不一致性检测表明,直接比较与间接比较无显著的不一致性。异质性检验显示研究间不存在统计学异质性。结论充分比较新型口服抗凝药的有效性、安全性及经济性,阿哌沙班排序最佳,可考虑首选。展开更多
基金Supported by The Natural Science Foundation of Hubei Province,No.2013CFA076
文摘AIM:To systematically evaluate the association between the miR-146 a rs2910164 polymorphism and susceptibility to gastric cancer.METHODS:A comprehensive electronic search was conducted for articles published up until January 27,2014 in Medline(PubMed),Excerpta Medica Database(Embase),the Cochrane Library and Google Scholar.Only case-control studies published in English that evaluated the association between the miR-146 a rs2910164 polymorphism and susceptibility to gastric cancer were included.Furthermore,only studies with sufficient data allowing for calculation of odds ratio(OR) and corresponding 95% confidence interval(CI) were included.These values were used in the quantitative synthesis to assess the strength of the association between the miR-146 a rs2910164 polymorphism and risk of gastric cancer.RESULTS:The database search identified 1002 eligible studies,of which seven(comprising 4112 cases and 5811 controls) were included for the meta-analysis.The results indicate that miR-146 a rs2910164 polymorphism is more likely to be associated with gastric cancer risk.In the overall analysis,a significantly increased cancer risk was found in the heterozygote(GG vs GC) comparison(OR = 1.14,95%CI:1.03-1.27; P = 0.01 for pooled OR).In the ethnicity subgroup analysis,a similar result was found among Caucasians(OR = 1.36,95%CI:1.01-1.85; P = 0.04 for pooled OR).In the stratified analysis by quality of studies,a significantly increased cancer risk was found in the heterozygote comparison among high quality studies(OR = 1.12,95%CI:1.01-1.26; P = 0.04 for pooled OR).When stratified on the basis of sample size,a significantly increased cancer risk was found among small sample size subgroups for the allelic(G vs C:OR = 1.16,95%CI:1.03-1.30; P = 0.01),homozygote(GG vs CC:OR = 1.33,95%CI:1.03-1.73; P = 0.03) and recessive model(GG vs GC + CC:OR = 0.05,95%CI:0.00-0.10; P = 0.03) comparisons.CONCLUSION:The miR-146 a rs2910164 polymorphism is associated with increased gastric cancer risk,particularly evident in high quality studies with small sample sized Caucasian populations.
文摘目的系统评价新型口服抗凝药(达比加群酯、利伐沙班、阿哌沙班及依度沙班)用于非瓣膜性房颤治疗的有效性和安全性。方法计算机检索截止2016年9月,在Pubmed,Embase,Medline,Cochrane,Clinical Trials.gov,Web of Science,中国知网、万方及维普数据库中检索关于新型口服抗凝药用于非瓣膜性房颤治疗的随机对照研究,根据纳入标准和排除标准对文献进行筛选和质量评价,使用Rev Man 5.3和Stata 13.1软件对数据进行网络Meta分析。结果共纳入17篇随机对照研究,总计83 561例患者。网络Meta分析结果显示,新型口服抗凝药预防全因死亡率的作用按照由高至低依次排序为利伐沙班,阿哌沙班,依度沙班,达比加群酯;治疗卒中和体循环栓塞的作用按照由高至低依次排序为利伐沙班,达比加群酯,阿哌沙班,依度沙班;治疗缺血性卒中的作用按照由高至低依次排序为利伐沙班,阿哌沙班,达比加群酯,依度沙班;严重出血率按照由低至高依次排序为依度沙班,阿哌沙班,达比加群酯,利伐沙班;颅内出血率按照由低至高依次排序为达比加群酯,依度沙班,阿哌沙班,利伐沙班;心肌梗死率按照由低至高依次排序为利伐沙班,阿哌沙班,依度沙班,达比加群酯。所有结局指标的不一致性检测表明,直接比较与间接比较无显著的不一致性。异质性检验显示研究间不存在统计学异质性。结论充分比较新型口服抗凝药的有效性、安全性及经济性,阿哌沙班排序最佳,可考虑首选。
